Olalekan Oluwole
Overview
Explore the profile of Olalekan Oluwole including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1352
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jallouk A, Oluwole O, Dholaria B
Bone Marrow Transplant
. 2025 Jan;
PMID: 39825018
No abstract available.
2.
Thompson J, Schneider B, Brahmer J, Zaid M, Achufusi A, Armand P, et al.
J Natl Compr Canc Netw
. 2024 Nov;
22(9):582-592.
PMID: 39536465
The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur...
3.
Bhaskar S, Dholaria B, Savani B, Sengsayadeth S, Oluwole O
Clin Hematol Int
. 2024 Oct;
6(4):93-99.
PMID: 39469119
No abstract available.
4.
Shah R, Murphy D, Logue M, Jerkins J, Jallouk A, Adetola K, et al.
Clin Hematol Int
. 2024 Oct;
6(4):74-88.
PMID: 39469117
Chronic graft-versus-host disease (cGVHD) represents a common long-term complication after allogeneic hematopoietic stem cell transplantation (HSCT). It imposes a significant morbidity burden and is the leading cause of non-relapse mortality...
5.
Shah B, Mattison R, Abboud R, Abdelmessieh P, Aldoss I, Burke P, et al.
J Natl Compr Canc Netw
. 2024 Oct;
22(8):563-576.
PMID: 39413812
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) provide recommendations for management of ALL, with a focus on the classification of ALL subtypes based...
6.
Jallouk A, Sengsayadeth S, Savani B, Dholaria B, Oluwole O
Clin Hematol Int
. 2024 Oct;
6(3):61-72.
PMID: 39351308
No abstract available.
7.
Montoya M, Harmsen H, Baer B, Long N, Messimore A, Jayani R, et al.
Bone Marrow Transplant
. 2024 Sep;
59(12):1780-1782.
PMID: 39256585
No abstract available.
8.
Jain M, Spiegel J, Nastoupil L, Tamaresis J, Ghobadi A, Lin Y, et al.
J Clin Oncol
. 2024 Aug;
42(30):3581-3592.
PMID: 39094076
Purpose: Axicabtagene ciloleucel (axi-cel) is an autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that is approved for the treatment of relapsed or refractory large B-cell lymphoma. Little is known...
9.
Bhaskar S, Dholaria B, Savani B, Oluwole O
Clin Hematol Int
. 2024 Jul;
6(3):9-16.
PMID: 39027142
Chimeric antigen receptor (CAR) T-cell therapy has gained wide used across an array of hematologic malignancies. Though CAR T therapy has changed outcomes in the treatment of many malignancies its...
10.
Knight E T, Oluwole O, Kitko C
Clin Hematol Int
. 2024 May;
6(1):96-115.
PMID: 38817691
CD19-directed Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL). Somewhat uniquely among oncologic clinical trials, early clinical development occurred simultaneously...